8-K Announcements
6Material company update
Apr 30, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Bristol-Myers Squibb Company(BMY)Earnings, Financials & Key Ratios
BMY•NYSE
15.7× P/E·Price updated Jun 19, 2026
AboutBristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.Show more
- Revenue$48.19B-0.2%
- EBITDA$16.56B-14.0%
- Net Income$7.05B+178.8%
- EPS (Diluted)3.45+178.2%
- Gross Margin67.65%+19.1%
- EBITDA Margin34.35%-13.8%
- Operating Margin26.34%+31.7%
- Net Margin14.63%+179.0%
- ROE40.43%+203.6%
BMY Key Insights
Bristol-Myers Squibb Company (BMY) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 26.7% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 4.6%
✗Weaknesses
- ✗High debt to equity ratio of 2.5x
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BMY posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMY Price & Volume
Bristol-Myers Squibb Company (BMY) stock price & volume — 10-year historical chart
Loading chart...
BMY Growth Metrics
Bristol-Myers Squibb Company (BMY) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.27%
5 Years2.54%
3 Years1.45%
TTM1.78%
Profit CAGR
10 Years16.25%
5 Years-
3 Years3.69%
TTM34.25%
EPS CAGR
10 Years13.53%
5 Years-
3 Years5.36%
TTM33.57%
Return on Capital
10 Years14.84%
5 Years13.09%
3 Years14.61%
Last Year18.75%
BMY Recent Earnings
Bristol-Myers Squibb Company (BMY) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
Apr 30, 2026Metric
Actual
Est
EPS
$1.58+11.3%
$1.42
Rev
$11.5B+5.1%
$10.9B
Q1 2026
Feb 5, 2026Metric
Actual
Est
EPS
$1.26+2.4%
$1.23
Rev
$12.5B+1.8%
$12.3B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$1.63+7.2%
$1.52
Rev
$12.2B+3.1%
$11.9B
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$1.46+33.9%
$1.09
Rev
$12.3B+7.2%
$11.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 30, 2026 | $1.58vs $1.42+11.3% | $11.5Bvs $10.9B+5.1% |
| Q1 2026 | Feb 5, 2026 | $1.26vs $1.23+2.4% | $12.5Bvs $12.3B+1.8% |
| Q4 2025 | Oct 30, 2025 | $1.63vs $1.52+7.2% | $12.2Bvs $11.9B+3.1% |
| Q3 2025 | Jul 31, 2025 | $1.46vs $1.09+33.9% | $12.3Bvs $11.4B+7.2% |
Based on last 12 quarters of dataView full earnings history →
BMY Peer Comparison
Bristol-Myers Squibb Company (BMY) competitors in Large diversified branded pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 GILD | 153.66B | 123.76 | 18.25 | 2.39% | 30.99% | 42.33% | 1.09 |
Compare BMY vs Peers
Bristol-Myers Squibb Company (BMY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMY Income Statement
Bristol-Myers Squibb Company (BMY) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 20.78B | 22.56B | 26.14B | 42.52B | 46.38B | 46.16B | 45.01B | 48.3B | 48.19B | 48.48B |
Revenue Growth % | 6.94% | 8.59% | 15.89% | 62.62% | 9.1% | -0.49% | -2.5% | 7.32% | -0.22% | 1.78% |
Cost of Goods Sold | 5.82B | 6.49B | 8.89B | 20.82B | 19.62B | 19.67B | 19.65B | 20.87B | 15.59B | 15.15B |
COGS % of Revenue | 28% | 28.75% | 34.02% | 48.96% | 42.31% | 42.61% | 43.66% | 43.2% | 32.35% | - |
Gross Profit | 14.96B▲ 0% | 16.07B▲ 7.5% | 17.25B▲ 7.3% | 21.7B▲ 25.8% | 26.76B▲ 23.3% | 26.49B▼ 1.0% | 25.36B▼ 4.3% | 27.43B▲ 8.2% | 32.6B▲ 18.8% | 33.33B▲ 0% |
Gross Margin % | 72% | 71.25% | 65.98% | 51.04% | 57.69% | 57.39% | 56.34% | 56.79% | 67.65% | 68.75% |
Gross Profit Growth % | 3.19% | 7.47% | 7.31% | 25.8% | 23.32% | -1.01% | -4.28% | 8.18% | 18.85% | - |
Operating Expenses | 9.72B | 9.68B | 10.81B | 17.21B | 17.22B | 17.22B | 16.89B | 17.77B | 19.91B | 20.88B |
OpEx % of Revenue | 46.78% | 42.91% | 41.35% | 40.47% | 37.13% | 37.3% | 37.52% | 36.8% | 41.3% | - |
Selling, General & Admin | 4.75B | 4.55B | 4.86B | 7.65B | 7.69B | 7.81B | 7.68B | 7.87B | 7.24B | 7.28B |
SG&A % of Revenue | 22.86% | 20.17% | 18.6% | 17.99% | 16.57% | 16.92% | 17.06% | 16.28% | 15.03% | - |
Research & Development | 4.97B | 5.13B | 5.95B | 9.56B | 9.53B | 9.41B | 9.21B | 9.78B | 9.61B | 10.03B |
R&D % of Revenue | 23.92% | 22.74% | 22.75% | 22.48% | 20.55% | 20.39% | 20.46% | 20.25% | 19.94% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 127M | 3.05B | 3M |
Operating Income | 5.24B▲ 0% | 6.39B▲ 22.0% | 6.44B▲ 0.7% | 4.49B▼ 30.2% | 9.54B▲ 112.4% | 9.27B▼ 2.8% | 8.47B▼ 8.6% | 9.66B▲ 14.0% | 12.7B▲ 31.5% | 12.45B▲ 0% |
Operating Margin % | 25.22% | 28.34% | 24.63% | 10.56% | 20.57% | 20.08% | 18.82% | 20% | 26.34% | 25.67% |
Operating Income Growth % | 1.16% | 22.05% | 0.7% | -30.24% | 112.38% | -2.82% | -8.62% | 14% | 31.46% | - |
EBITDA | 6.03B | 7.03B | 8.19B | 14.87B | 20.23B | 19.55B | 18.23B | 19.26B | 16.56B | 15.73B |
EBITDA Margin % | 29.01% | 31.16% | 31.31% | 34.98% | 43.6% | 42.35% | 40.51% | 39.87% | 34.35% | 32.45% |
EBITDA Growth % | 8.4% | 16.64% | 16.41% | 81.7% | 36% | -3.36% | -6.73% | 5.63% | -14.03% | -17.22% |
D&A (Non-Cash Add-back) | 789M | 637M | 1.75B | 10.38B | 10.69B | 10.28B | 9.76B | 9.6B | 3.86B | 3.29B |
EBIT | 5.33B | 6.15B | 5.63B | -5.45B | 9.43B | 8.95B | 9.61B | -6.43B | 10.68B | 10.49B |
Net Interest Income | -196M | -183M | -656M | -1.42B | -1.33B | -1.23B | -1.17B | -1.95B | -1.21B | -716M |
Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 300M | 300M |
Interest Expense | 196M | 183M | 656M | 1.42B | 1.33B | 1.23B | 1.17B | 1.95B | 1.51B | 1.02B |
Other Income/Expense | -108M | -426M | -1.46B | -11.36B | -1.44B | -1.56B | -32M | -18.04B | -3.37B | -2.85B |
Pretax Income | 5.13B▲ 0% | 5.97B▲ 16.3% | 4.97B▼ 16.6% | -6.87B▼ 238.1% | 8.1B▲ 217.9% | 7.71B▼ 4.8% | 8.44B▲ 9.4% | -8.38B▼ 199.3% | 9.33B▲ 211.3% | 9.6B▲ 0% |
Pretax Margin % | 24.7% | 26.45% | 19.03% | -16.16% | 17.46% | 16.71% | 18.75% | -17.35% | 19.36% | 19.79% |
Income Tax | 4.16B | 1.02B | 1.51B | 2.12B | 1.08B | 1.37B | 400M | 554M | 2.27B | 2.32B |
Effective Tax Rate % | 81% | 17.11% | 30.45% | -30.91% | 13.39% | 17.74% | 4.74% | -6.61% | 24.36% | 24.22% |
Net Income | 1.01B▲ 0% | 4.92B▲ 388.6% | 3.44B▼ 30.1% | -8.99B▼ 361.6% | 6.99B▲ 177.8% | 6.33B▼ 9.5% | 8.03B▲ 26.8% | -8.95B▼ 211.5% | 7.05B▲ 178.8% | 7.28B▲ 0% |
Net Margin % | 4.85% | 21.81% | 13.15% | -21.16% | 15.08% | 13.71% | 17.83% | -18.53% | 14.63% | 15.01% |
Net Income Growth % | -77.41% | 388.58% | -30.1% | -361.56% | 177.75% | -9.54% | 26.84% | -211.5% | 178.82% | 34.25% |
Net Income (Continuing) | 975M | 4.95B | 3.46B | -8.99B | 7.01B | 6.34B | 8.04B | -8.93B | 7.06B | 7.27B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 106M | 96M | 100M | 60M | 60M | 57M | 55M | 53M | 33M | 34M |
EPS (Diluted) | 0.61▲ 0% | 3.03▲ 396.7% | 2.01▼ 33.7% | -3.98▼ 298.0% | 3.12▲ 178.4% | 2.95▼ 5.4% | 3.86▲ 30.8% | -4.41▼ 214.2% | 3.45▲ 178.2% | 3.56▲ 0% |
EPS Growth % | -76.98% | 396.72% | -33.66% | -298.01% | 178.39% | -5.45% | 30.85% | -214.25% | 178.23% | 33.57% |
EPS (Basic) | 0.61 | 3.03 | 2.02 | -3.98 | 3.15 | 2.97 | 3.88 | -4.41 | 3.46 | - |
Diluted Shares Outstanding | 1.65B | 1.64B | 1.71B | 2.26B | 2.25B | 2.15B | 2.08B | 2.03B | 2.04B | 2.04B |
Basic Shares Outstanding | 1.65B | 1.63B | 1.71B | 2.26B | 2.22B | 2.13B | 2.07B | 2.03B | 2.04B | 2.04B |
Dividend Payout Ratio | 255.91% | 53.11% | 77.9% | - | 62.85% | 73.24% | 59.12% | - | 71.53% | - |
BMY Balance Sheet
Bristol-Myers Squibb Company (BMY) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 14.85B | 17.72B | 29.35B | 30.19B | 33.26B | 27.27B | 31.77B | 29.78B | 29.39B | 27.21B |
Cash & Short-Term Investments | 6.81B | 8.76B | 15.39B | 16.45B | 17.22B | 9.25B | 12.28B | 10.86B | 10.67B | 10.49B |
Cash Only | 5.42B | 6.91B | 12.35B | 14.55B | 13.98B | 9.12B | 11.46B | 10.35B | 10.21B | 9.57B |
Short-Term Investments | 1.39B | 1.85B | 3.05B | 1.9B | 3.24B | 130M | 816M | 513M | 464M | 912M |
Accounts Receivable | 6.3B | 5.75B | 7.68B | 10.55B | 12.52B | 13.94B | 15.26B | 14.42B | 14.53B | 9.37B |
Days Sales Outstanding | 110.68 | 92.98 | 107.29 | 90.6 | 98.49 | 110.21 | 123.79 | 109 | 110.01 | 100.9 |
Inventory | 1.17B | 1.2B | 4.29B | 2.07B | 2.1B | 2.34B | 2.66B | 2.56B | 2.69B | 2.76B |
Days Inventory Outstanding | 73.15 | 67.25 | 176.16 | 36.36 | 38.97 | 43.41 | 49.45 | 44.72 | 62.97 | 65.89 |
Other Current Assets | 0 | 899M | 1.23B | -685M | 1.43B | 1.74B | 1.56B | 1.94B | 1.5B | 4.6B |
Total Non-Current Assets | 18.7B | 17.27B | 100.59B | 88.29B | 76.05B | 69.55B | 63.39B | 62.82B | 60.65B | 59.27B |
Property, Plant & Equipment | 5B | 5.03B | 6.96B | 6.75B | 6.97B | 7.47B | 8.04B | 8.36B | 9.13B | 7.66B |
Fixed Asset Turnover | 4.15x | 4.49x | 3.76x | 6.30x | 6.66x | 6.18x | 5.60x | 5.78x | 5.28x | 5.92x |
Goodwill | 6.86B | 6.54B | 22.49B | 20.55B | 20.5B | 21.15B | 21.17B | 21.72B | 21.75B | 21.74B |
Intangible Assets | 1.21B | 1.09B | 63.97B | 53.45B | 42.77B | 36.35B | 27.48B | 23.64B | 19.1B | 18.24B |
Long-Term Investments | 2.48B | 1.77B | 4.17B | 4.51B | 2.71B | 2.19B | 2.5B | 2.51B | 2.51B | 7.12B |
Other Non-Current Assets | 1.53B | 2.02B | 2.5B | 1.88B | 1.66B | 1.04B | 1.43B | 2.36B | 2.78B | 6.45B |
Total Assets | 33.55B▲ 0% | 34.99B▲ 4.3% | 129.94B▲ 271.4% | 118.48B▼ 8.8% | 109.31B▼ 7.7% | 96.82B▼ 11.4% | 95.16B▼ 1.7% | 92.6B▼ 2.7% | 90.04B▼ 2.8% | 86.48B▲ 0% |
Asset Turnover | 0.62x | 0.64x | 0.20x | 0.36x | 0.42x | 0.48x | 0.47x | 0.52x | 0.54x | 0.53x |
Asset Growth % | -0.46% | 4.28% | 271.42% | -8.82% | -7.74% | -11.43% | -1.72% | -2.69% | -2.77% | -5.74% |
Total Current Liabilities | 9.56B | 10.65B | 18.3B | 19.08B | 21.87B | 21.89B | 22.26B | 23.77B | 23.42B | 19.16B |
Accounts Payable | 2.25B | 1.89B | 2.44B | 2.71B | 2.95B | 3.04B | 3.26B | 3.6B | 3.58B | 4.23B |
Days Payables Outstanding | 141.03 | 106.47 | 100.33 | 47.57 | 54.85 | 56.41 | 60.54 | 63 | 83.69 | 105.53 |
Short-Term Debt | 987M | 1.7B | 3.35B | 2.34B | 4.95B | 4.26B | 3.12B | 2.05B | 2.26B | 2.31B |
Deferred Revenue (Current) | 83M | 172M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 909M | 5.75B | 9.35B | 11.65B | 11.48B | 11.99B | 12.79B | 14.6B | 14.63B | 12.62B |
Current Ratio | 1.55x | 1.66x | 1.60x | 1.58x | 1.52x | 1.25x | 1.43x | 1.25x | 1.26x | 1.42x |
Quick Ratio | 1.43x | 1.55x | 1.37x | 1.47x | 1.43x | 1.14x | 1.31x | 1.15x | 1.14x | 1.28x |
Cash Conversion Cycle | 42.8 | 53.75 | 183.12 | 79.4 | 82.6 | 97.2 | 112.7 | 90.72 | 89.29 | 61.26 |
Total Non-Current Liabilities | 12.14B | 10.21B | 59.94B | 61.52B | 51.44B | 43.81B | 43.41B | 52.44B | 48.12B | 47.22B |
Long-Term Debt | 6.97B | 5.65B | 43.39B | 48.34B | 39.6B | 35.06B | 36.65B | 47.6B | 42.85B | 42.15B |
Capital Lease Obligations | 0 | 0 | 672M | 833M | 874M | 1.26B | 1.53B | 1.37B | 1.83B | 5.22B |
Deferred Tax Liabilities | 0 | 19M | 6.45B | 5.41B | 4.5B | 2.17B | 338M | 369M | 222M | 905M |
Other Non-Current Liabilities | 4.71B | 4.07B | 9.01B | 6.59B | 6.13B | 5.05B | 4.59B | 2.87B | 3.05B | 4.85B |
Total Liabilities | 21.7B | 20.86B | 78.25B | 80.6B | 73.31B | 65.7B | 65.67B | 76.22B | 71.53B | 66.37B |
Total Debt | 7.96B | 7.35B | 47.54B | 51.67B | 45.6B | 40.72B | 41.46B | 51.2B | 47.14B | 44.46B |
Net Debt | 2.54B | 438M | 35.19B | 37.13B | 31.62B | 31.59B | 30B | 40.85B | 36.93B | 34.89B |
Debt / Equity | 0.67x | 0.52x | 0.92x | 1.36x | 1.27x | 1.31x | 1.41x | 3.12x | 2.55x | 2.21x |
Debt / EBITDA | 1.32x | 1.05x | 5.81x | 3.47x | 2.25x | 2.08x | 2.27x | 2.66x | 2.85x | 2.83x |
Net Debt / EBITDA | 0.42x | 0.06x | 4.30x | 2.50x | 1.56x | 1.62x | 1.65x | 2.12x | 2.23x | 2.22x |
Interest Coverage | 27.18x | 33.61x | 8.58x | -3.84x | 7.07x | 7.26x | 8.24x | -3.30x | 7.08x | 10.33x |
Total Equity | 11.85B▲ 0% | 14.13B▲ 19.2% | 51.7B▲ 266.0% | 37.88B▼ 26.7% | 36.01B▼ 5.0% | 31.12B▼ 13.6% | 29.48B▼ 5.2% | 16.39B▼ 44.4% | 18.51B▲ 12.9% | 20.1B▲ 0% |
Equity Growth % | -27.53% | 19.25% | 265.95% | -26.72% | -4.95% | -13.58% | -5.25% | -44.42% | 12.92% | 38.74% |
Book Value per Share | 7.17 | 8.63 | 30.20 | 16.78 | 16.04 | 14.50 | 14.19 | 8.08 | 9.07 | 9.84 |
Total Shareholders' Equity | 11.74B | 14.03B | 51.6B | 37.82B | 35.95B | 31.06B | 29.43B | 16.34B | 18.47B | 20.07B |
Common Stock | 221M | 221M | 292M | 292M | 292M | 292M | 292M | 292M | 292M | 292M |
Retained Earnings | 31.16B | 34.06B | 34.47B | 21.28B | 23.82B | 25.5B | 28.77B | 14.91B | 16.9B | 18.29B |
Treasury Stock | -19.25B | -19.57B | -25.36B | -26.24B | -31.26B | -38.62B | -43.77B | -43.66B | -43.58B | 0 |
Accumulated OCI | -2.29B | -2.76B | -1.52B | -1.84B | -1.27B | -1.28B | -1.55B | -1.24B | -1.52B | -1.37B |
Minority Interest | 106M | 96M | 100M | 60M | 60M | 57M | 55M | 53M | 33M | 34M |
BMY Cash Flow Statement
Bristol-Myers Squibb Company (BMY) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 5.28B | 7.07B | 8.21B | 14.05B | 16.21B | 13.07B | 13.86B | 15.19B | 14.16B | 13.31B |
Operating CF Margin % | 25.39% | 31.32% | 31.4% | 33.05% | 34.94% | 28.31% | 30.8% | 31.45% | 29.37% | - |
Operating CF Growth % | 72.5% | 33.95% | 16.19% | 71.16% | 15.34% | -19.38% | 6.08% | 9.6% | -6.81% | -17.75% |
Net Income | 975M | 4.95B | 3.46B | -8.99B | 7.01B | 6.34B | 8.04B | -8.93B | 7.05B | 7.28B |
Depreciation & Amortization | 789M | 637M | 1.75B | 10.38B | 10.69B | 10.28B | 9.76B | 9.6B | 4.01B | 3.59B |
Stock-Based Compensation | 199M | 221M | 441M | 779M | 583M | 457M | 518M | 507M | 553M | 555M |
Deferred Taxes | 453M | 45M | -924M | 983M | -1.39B | -2.74B | -3.29B | -2.09B | -965M | -1.03B |
Other Non-Cash Items | 714M | 999M | 317M | 9.92B | 578M | 955M | 744M | 15.29B | 3.96B | 4.5B |
Working Capital Changes | 2.15B | 217M | 3.17B | 983M | -1.26B | -2.23B | -1.91B | 810M | -455M | -1.59B |
Change in Receivables | -431M | -429M | 752M | -646M | -1.05B | -663M | -995M | 264M | -295M | 1.38B |
Change in Inventory | -29M | -216M | 463M | 2.67B | 13M | -69M | -751M | -486M | -184M | -1M |
Change in Payables | 320M | -59M | 229M | 188M | 245M | 109M | 198M | 184M | -2M | 492M |
Cash from Investing | -66M | -2B | -9.91B | -10.86B | -538M | -1.06B | -2.29B | -21.35B | -4.13B | -3.76B |
Capital Expenditures | -1.05B | -951M | -836M | -753M | -973M | -1.12B | -1.21B | -1.25B | -1.31B | -1.4B |
CapEx % of Revenue | 5.08% | 4.22% | 3.2% | 1.77% | 2.1% | 2.42% | 2.69% | 2.58% | 2.72% | 2.88% |
Acquisitions | 10M | -1.12B | -9.09B | -12.34B | -862M | -2.98B | -260M | -20.72B | -2.87B | -3.9B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.1B |
Cash from Financing | -4.08B | -3.54B | 7.62B | -1.15B | -16.22B | -16.96B | -9.42B | 5.13B | -10.35B | -10.91B |
Debt Issued (Net) | 991M | -548M | 17.65B | 3.93B | -6.18B | -5.31B | 456M | 10.1B | -5.17B | -5.72B |
Equity Issued (Net) | -2.47B | -320M | -7.3B | -1.55B | -6.29B | -8B | -5.16B | 0 | -128M | -134M |
Dividends Paid | -2.58B | -2.61B | -2.68B | -4.08B | -4.4B | -4.63B | -4.74B | -4.86B | -5.04B | -5.07B |
Share Repurchases | -2.47B | -320M | -7.3B | -1.55B | -6.29B | -8B | -5.16B | 0 | 0 | -98M |
Other Financing | -22M | -54M | -53M | 542M | 641M | 984M | 27M | -106M | 0 | 11M |
Net Change in Cash | 1.18B▲ 0% | 1.49B▲ 25.8% | 5.91B▲ 296.6% | 2.15B▼ 63.6% | -657M▼ 130.5% | -4.99B▼ 659.7% | 2.19B▲ 144.0% | -1.17B▼ 153.4% | -137M▲ 88.3% | -1.29B▲ 0% |
Free Cash Flow | 4.22B▲ 0% | 6.12B▲ 44.9% | 7.37B▲ 20.6% | 13.3B▲ 80.3% | 15.23B▲ 14.5% | 11.95B▼ 21.6% | 12.65B▲ 5.9% | 13.94B▲ 10.2% | 12.85B▼ 7.9% | 11.91B▲ 0% |
FCF Margin % | 20.31% | 27.1% | 28.2% | 31.28% | 32.84% | 25.88% | 28.11% | 28.87% | 26.65% | 24.56% |
FCF Growth % | 128.97% | 44.91% | 20.59% | 80.35% | 14.55% | -21.57% | 5.88% | 10.2% | -7.87% | -9% |
FCF per Share | 2.55 | 3.74 | 4.31 | 5.89 | 6.79 | 5.57 | 6.09 | 6.88 | 6.29 | 5.83 |
FCF Conversion (FCF/Net Income) | 5.24x | 1.44x | 2.39x | -1.56x | 2.32x | 2.07x | 1.73x | -1.70x | 2.01x | 1.64x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
BMY Key Ratios
Bristol-Myers Squibb Company (BMY) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 7.14% | 37.88% | 10.45% | -20.08% | 18.93% | 18.85% | 26.48% | -39.01% | 40.43% | 38.96% |
Return on Invested Capital (ROIC) | 23.67% | 33.13% | 9.52% | 4.16% | 10.03% | 10.67% | 10.4% | 12.41% | 16.9% | 16.96% |
Gross Margin | 72% | 71.25% | 65.98% | 51.04% | 57.69% | 57.39% | 56.34% | 56.79% | 67.65% | 68.75% |
Net Margin | 4.85% | 21.81% | 13.15% | -21.16% | 15.08% | 13.71% | 17.83% | -18.53% | 14.63% | 15.01% |
Debt / Equity | 0.67x | 0.52x | 0.92x | 1.36x | 1.27x | 1.31x | 1.41x | 3.12x | 2.55x | 2.21x |
Interest Coverage | 27.18x | 33.61x | 8.58x | -3.84x | 7.07x | 7.26x | 8.24x | -3.30x | 7.08x | 10.33x |
FCF Conversion | 5.24x | 1.44x | 2.39x | -1.56x | 2.32x | 2.07x | 1.73x | -1.70x | 2.01x | 1.64x |
Revenue Growth | 6.94% | 8.59% | 15.89% | 62.62% | 9.1% | -0.49% | -2.5% | 7.32% | -0.22% | 1.78% |
Related:BMY Dividend History·BMY Revenue History·BMY Price History·BMY P/E History·BMY Financial Ratios·BMY Institutional Holders
BMY SEC Filings & Documents
Bristol-Myers Squibb Company (BMY) SEC filings — annual & quarterly reports (10-K, 10-Q)
BMY Frequently Asked Questions
Bristol-Myers Squibb Company (BMY) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Bristol-Myers Squibb Company (BMY) reported $48.48B in revenue for fiscal year 2025. This represents a 222% increase from $15.06B in 1996.
Bristol-Myers Squibb Company (BMY) saw revenue decline by 0.2% over the past year.
Yes, Bristol-Myers Squibb Company (BMY) is profitable, generating $7.28B in net income for fiscal year 2025 (14.6% net margin).
Dividend & Returns
Yes, Bristol-Myers Squibb Company (BMY) pays a dividend with a yield of 4.58%. This makes it attractive for income-focused investors.
Bristol-Myers Squibb Company (BMY) has a return on equity (ROE) of 40.4%. This is excellent, indicating efficient use of shareholder capital.
Bristol-Myers Squibb Company (BMY) generated $11.91B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.